Paolo Pozzilli, MD is Professor of Endocrinology and Metabolism at University Campus BioMedico in Rome where is Director of the Unit of Endocrinology & Diabetes and of the PostGraduate School of Endocrinology & Metabolic Diseases. He is the coordinator of the PhD Program in Integrated Biomedical Sciences and Bioethics. He is also Professor of Diabetes and Clinical Research at the Blizard Institute, St. Bartholomew’s and the London School of Medicine, Queen Mary University of London. Very recently, he was Visiting Professor at the Joslin Diabetes Center in Boston, Harvard University. Dr. Pozzilli’s main research activities include the study of the pathogenesis of type 1 diabetes and its complications, the introduction of novel treatments and the application of technology to the management of diabetes. He participated in the design of algorithms for treatment of type 2 diabetes and has been principal investigator for more than 50 clinical trials in diabetes. Most recent trials include Roadmap, In Tandem-2, Exscel and Canvas, all published in the New England Journal of Medicine. Recent drug projects include antidiabetics such as SGLT-2, GLP-1, novel forms of insulin and novel technology applied to diabetes care. For his research, Dr. Pozzilli is funded at present by the Juvenile Diabetes Research Foundation (USA), the EFSD Foundation, the Italian Ministry of University and the Italian Ministry of Health. His international reputation established over 30 years of diabetes research is reflected in special lectures given at the American Diabetes Association, the European Association for the Study of Diabetes (EASD), the International Diabetes Federation, organizing and chairing 18 international symposia on the occasion of the EASD congresses and 22 Bart's International Symposia in London since 1996. He was among the first to describe cell-mediated immune reactivity in type 1 diabetes and championed the concept of immunotherapy in this disease by carrying out 14 IMDIAB trials (see IMDIAB on Pubmed).